期刊文献+

多重耐药鲍曼不动杆菌医院获得性肺炎的危险因素及预后分析 被引量:41

Risk factors and prognosis of hospital-acquired pneumonia due to multidrugresistant Acinetobacter baumannii
下载PDF
导出
摘要 目的分析多重耐药鲍曼不动杆菌(MDRAB)医院获得性肺炎(HAP)患者的危险因素及死亡预后因素,以期指导临床工作,减少多重耐药菌的发生及降低病死率。方法采用病例对照的研究方法,回顾性分析2009年1月—2012年12月中山大学附属江门市中心医院MDRAB HAP84例,并选取同时期非MDRAB HAP153例作为对照组,应用单因素分析(t检验和χ2检验)及多因素Logistic回归分析MDRAB HAP的危险因素。将84例MDRAB HAP患者分为死亡组21例和存活组63例,应用上述方法分析MDRAB HAP死亡的预后因素。结果单因素分析发现,MDRAB HAP的危险因素包括:合并其他细菌感染、机械通气≥7 d、气管插管/切开、感染前使用舒巴坦合剂、感染前使用碳青霉烯类、感染前使用抗菌药物≥3种以及感染时APACHEⅡ评分≥20分等。再进行Logistic多因素回归分析,结果显示感染时APACHEⅡ评分≥20分(OR=4.10)、机械通气≥7 d(OR=3.03)、感染前使用碳青霉烯类(OR=2.34)是MDRAB HAP的独立危险因素。预后因素单因素分析,MDRAB HAP死亡的危险因素包括:感染前使用抗菌药物≥3种、感染时APACHEⅡ评分≥20分、治疗3 d后临床肺部感染评分(CPIS)升高、细菌(鲍曼不动杆菌)未清除、治疗后转为泛耐药菌等。再进行Logistic多因素回归分析发现,感染时APACHEⅡ评分≥20分(OR=2.14)、治疗3 d后CPIS升高(OR=1.87)、细菌未清除(OR=5.37)及治疗后转为泛耐药菌(OR=1.79)是导致MDRAB HAP死亡的预后因素。结论感染时APACHEⅡ评分≥20分、机械通气≥7 d、感染前使用碳青霉烯类是感染MDRAB HAP的独立危险因素;感染时APACHEⅡ评分≥20分、治疗3 d后CPIS升高、细菌未清除及治疗后转为泛耐药菌是MDRAB HAP死亡的预后因素。 Objective To analyze the risk factors and prognosis of hospital-acquired pneumonia due to multidrug-resistant Acinetobacter baumannii(MDRAB)for better prevention and control of such infections.Methods A total of 84 cases of hospital-acquired pneumonia caused by MDRAB were treated in Jiangmen Central Hospital during the period from January 2009 to December 2012.The clinical data of these patients were reviewed retrospectively.Additional 153 cases of hospital-acquired pneumonia caused by non-multidrug-resistant A.baumannii were included as control group.Univariate and multivariate logistic analysis were used to examine the risk factors of MDRAB pneumonia.The prognostic factors for the 84 cases of hospitalacquired pneumonia due to MDRAB were analyzed similarly by comparing the relevant factors between the 21 deaths and63 survivals.Results Univariate analysis found that the risk factors for MDRAB hospital-acquired pneumonia included mixed bacterial infection,mechanical ventilation≥7 days,endotracheal intubation/tracheotomy, use of sulbactambased therapies,carbapenems,or at least 3 antibiotics prior to infection,and APACHE II score≥20 at time of infection.Subsequent multivariate logistic analysis showed that APACHE II score≥20 at time of infection(OR=4.10),mechanical ventilation≥7 days(OR=3.03),use of carbapenems prior to infection(OR=2.34)were independent risk factors for MDRAB pneumonia.Univariate analysis revealed that the death of patients with hospital-acquired pneumonia was associated with use of at least 3 antibiotics prior to infection,APACHE II≥20 at time of infection,higher clinical pulmonary infection score(CPIS)after treatment for 3 days,persistent A.baumannii infection,extensively drug resistant A.baumannii.Multivariate logistic analysis found that APACHE II≥20 at time of infection(OR=2.14),higher CPIS after treatment for 3days(OR=1.87),persistent A.baumannii infection(OR=5.37),and extensively drug resistant A.baumannii(OR=1.79)were independent risk factors of death in patients with hospital-acquired pneumonia due to MDRAB.Conclusions APACHE II score≥20 at time of infection,mechanical ventilation≥7 days,and use of carbapenems prior to infection are independent risk factors for hospital-acquired pneumonia caused by MDRAB.APACHE II≥20 at time of infection,higher CPIS after treatment for 3 days,persistent A.baumannii infection,and extensively drug resistant A.baumannii are independent risk factors of patient death.
出处 《中国感染与化疗杂志》 CAS CSCD 北大核心 2015年第6期527-532,共6页 Chinese Journal of Infection and Chemotherapy
基金 广州市科技计划(2014J4100132) 广东省自然科学基金(S2012010008393)
关键词 鲍曼不动杆菌 多重耐药 医院获得性肺炎 危险因素 预后因素 Acinetobacter baumannii multidrug-resistant hospital-acquired pneumonia risk factor prognosis
  • 相关文献

参考文献13

  • 1胡付品,朱德妹,汪复,蒋晓飞,杨青,徐英春,张小江,孙自镛,陈中举,王传清,王爱敏,倪语星,孙景勇,俞云松,林洁,单斌,杜艳,徐元宏,沈继录,张泓,孔菁,卓超,苏丹虹,张朝霞,季萍,胡云建,艾效曼,黄文祥,贾蓓,魏莲花,吴玲.2011年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2012,12(5):321-329. 被引量:526
  • 2陈佰义,何礼贤,胡必杰,倪语星,邱海波,石岩,施毅,王辉,王明贵,杨毅,张菁,俞云松.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76-85. 被引量:838
  • 3Amrican Thoracic Sodety; Infectious Diseases Society of America. Guidelines for the management of adults with hospital- acquired, ventilator associated, and healthcare-associated pneumoilia[J]. Am J Respir Crit Care Med, 2005,171 (4) : 388- 416.
  • 4Munoz-Price LS, Weinstein RA. Acinetobacter infection[J]. N Engl J Meal,2008,358(2):1271 -1281.
  • 5Costa JI,Gomes do Amaral JL, Munechika M, et al. Severity and prognosis in intensive care: prospective application of the APACHE II index[J]. So Paulo Med J, 1999, 117 ( 5 ) : 205- 214.
  • 6Cisneros JM, Rodriguez-Bano J, Fernandez-Cuenca F, et al. Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study[J]. Clin Microbil Infect, 2005,11 (11 ) : 874-879.
  • 7Valles J, Fetter R. Bloodstream infection in the ICU [J]. Infect Dis Clin North Am, 2009,23(3):557-569.
  • 8Ye JJ, Huang CT, Shie SS, et al. Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains[J]. PLos One,2010,5(4): e9947.
  • 9Viana GF, dos Santos Saalfeld SM, Gardoso CL, et al. Evolution of antimierobial resistance of Acinetobacter baumammii in a university hospital[J]. Lett Appl Mierobiol, 2011,53 (3) : 374-378.
  • 10Adams-Haduch JM, Onuoha EO, Bogdanovich T, et al. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States [J]. Clin Microbiol, 2011, 49 (11) : 3849-3854.

二级参考文献13

  • 1周颖杰,李光辉.成人及儿童复杂性腹腔内感染的诊断与处理:美国外科感染学会及美国感染病学会指南[J].中国感染与化疗杂志,2010,10(4):241-247. 被引量:238
  • 2Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J]. N Engl J Med, 2009, 360(5) : 439-443.
  • 3Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Tweenty-first in- formational supplement, 2011, M100-S21 Vol 31 No. 1.
  • 4Falagas ME, Giannopoulou KP, Kokolakis GN, et al. Fosfo- mycin: use beyond urinary tract and gastrointestinal infec tions[J]. Clin Infect Dis, 2008, 46(7): 1069-1077.
  • 5Olsson-Liljequist B, Burman LG. Introducing fosfomycin for surgical prophylaxis-emergence of resistance in aerobic faecal gram-negative bacteria of in patients, but not among strains causing infection after elective colorectal procedures [J ]. Scand J Infect Dis, 1993, 25(6) :725-733.
  • 6Andaker L, Burman LG, Eklund A, et al. Fosfomycin/met- ronidazole compared with doxycycline/metronidazole for the prophylaxis of infection after elective coloreetal surgery: a randomised double blind multicentre trial in 517 patients[J]. Eur J Surg, 1992, 158(3):181 185.
  • 7Nohr M, Andersen JC, Juul-Jensen KE. Prophylactic single dose fosfomycin and metronidazole compared with neomycin, haeitraein, metronidazole and ampicillin in elective colorectal operations[J]. Acta Chir Seand, 1990, 156(3):223-230.
  • 8Lindhagen J, Hadziomerovic A, Nordlung S, et al. Comparison of systemic prophylaxis with metronidazole-fosfomycin and met- ronidazole-cephalothin in elective colorectal surgery[J]. Acta Chir Scand, 1981, 147(4):277-283.
  • 9方强.血管内导管相关感染的预防与治疗指南(2007)[J].中国实用外科杂志,2008,28(6):413-421. 被引量:391
  • 10汪复,朱德妹,胡付品,阮斐怡,倪语星,孙景勇,徐英春,孙宏莉,胡云健,艾效曼,俞云松,杨青,孙自镛,简翠,贾蓓,黄文祥,卓超,苏丹虹,魏莲花,吴玲,张朝霞,季萍,王传清,薛建昌,张泓,李万华.2007年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2008,8(5):325-333. 被引量:305

共引文献1329

同被引文献333

引证文献41

二级引证文献346

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部